July 15, 2023 — Four years ago, bimagrumab was a castoff from Novartis. That company had originally developed this monoclonal antibody for treating a rare muscle disease. But it failed spectacularly with disappointing results from a phase 2b study in 2016. That was a big disappointment, so it’s little wonder that Novartis walked away. Three years later, a glimmer […]
May 9, 2023 — With all the sensational reporting about semaglutide and tirzepatide for obesity – often with the emphasis on weight loss – you might think a revolution is underway. Yes, it is coming. But the truth is that it hasn’t even started yet. At present, for a number of reasons, we are barely scratching the surface of […]
January 12, 2022 — It’s been a long haul. But suddenly, we’re seeing a lot of optimism about anti-obesity medicines. Skeptics are yielding to stubborn facts about the impact of obesity on health. They are also yielding to good clinical data about the benefits of sound obesity care. So, too, are they seeing that newer generations of anti-obesity medicines […]
October 20, 2021 — Day by day, the prospects for treating obesity are getting better. Late on Monday, detailed results from the longest study yet of tirzepatide came out in Lancet. This was a study using this new drug in people with type 2 diabetes, but the average BMI of these patients was 33. None of them had a […]
February 22, 2021 — When NEJM recently published impressive results for a new obesity treatment, it caused quite a stir. Now it looks like semaglutide might have some serious competition coming right behind it. Late last week, Lilly announced results for two phase 3 studies of tirzepatide. These were both studies for type-2 diabetes. Effects on body weight were […]
